Search in:

Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3

Submit an article Journal homepage

141

Views

CrossRef citations to date

Altmetric

Review

Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models

Josephine Mauskopf RTI Health Solutions, 3040, Cornwallis Road, Research Triangle Park, NC 27709, USA; RTI Health Solutions, 3040, Cornwallis Road, Research Triangle Park, NC 27709, USA. [email protected]

Sandra Talbird RTI Health Solutions, 3040, Cornwallis Road, Research Triangle Park, NC 27709, USA

Baudouin Standaert GlaxoSmithKline Biologicals, Parc de la Noire Epine, Avenue Fleming 20, B-1300 Wavre, Belgium

Pages 357-371 | Published online: 09 Jan 2014

Cite this article
https://doi.org/10.1586/erp.12.11

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Cost–Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC. Oxford University Press, NY, USA (1996).
Google Scholar
Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF. Incorporating herd immunity effects into cohort models of vaccine cost–effectiveness. Med. Decis. Making 29(5), 557–569 (2009).
PubMed Web of Science ®Google Scholar
Soárez PC, Novaes HM, Sartori AM. Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making? Cad. Saude. Publica 25(Suppl. 3), S401–S414 (2009).
PubMed Web of Science ®Google Scholar
Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev. Vaccines 2(5), 649–660 (2003).
PubMedGoogle Scholar
Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 25(32), 5945–5957 (2007).
PubMed Web of Science ®Google Scholar
Bos JM, Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev. Pharmacoecon. Outcomes Res. 2(5), 443–455 (2002).
PubMedGoogle Scholar
Ferko N, Postma M, Gallivan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 26(Suppl. 5), F3–F15 (2008).
Web of Science ®Google Scholar
Kim SY, Goldie SJ. Cost–effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26(3), 191–215 (2008).
PubMed Web of Science ®Google Scholar
Boily MC, Abu-Raddad L, Desai K, Masse B, Self S, Anderson R. Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect. Dis. 8(3), 200–207 (2008).
PubMed Web of Science ®Google Scholar
Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 28(11), 2356–2359 (2010).
PubMed Web of Science ®Google Scholar
Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med. Decis. Making 23(1), 76–82 (2003).
PubMed Web of Science ®Google Scholar
Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev. 28, 88–100 (2006).
PubMed Web of Science ®Google Scholar
Jeurissen S, Makar A. Epidemiological and economic impact of human papillomavirus vaccines. Int. J. Gynecol. Cancer 19(4), 761–771 (2009).
PubMed Web of Science ®Google Scholar
Kauf TL. Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 28(6), 449–461 (2010).
PubMed Web of Science ®Google Scholar
Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost–effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 19(5), 518–531 (2010).
PubMed Web of Science ®Google Scholar
Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27(2), 127–147 (2009).
PubMed Web of Science ®Google Scholar
Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med. Decis. Making 26(5), 434–446 (2006).
PubMed Web of Science ®Google Scholar
Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost–utility of universal hepatitis A vaccination in Canada. Vaccine 25(51), 8536–8548 (2007).
PubMed Web of Science ®Google Scholar
Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28(12), 2370–2384 (2010).
PubMed Web of Science ®Google Scholar
Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost–effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann. Intern. Med. 151(12), 829–839 (2009).
PubMed Web of Science ®Google Scholar
Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost–effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann. Intern. Med. 151(12), 840–853 (2009).
PubMed Web of Science ®Google Scholar
Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008).
PubMed Web of Science ®Google Scholar
Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost–effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26(44), 5654–5661 (2008).
PubMed Web of Science ®Google Scholar
Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 22(13), 839–855 (2004).
PubMed Web of Science ®Google Scholar
Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 24(47–48), 6980–6989 (2006).
PubMed Web of Science ®Google Scholar
Levin A, Burgess C, Garrison LP Jr et al. Global eradication of measles: an epidemiologic and economic evaluation. J. Infect. Dis. 204(Suppl. 1), S98–S106 (2011).
Web of Science ®Google Scholar
Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost–effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9–10), 1316–1330 (2002).
PubMed Web of Science ®Google Scholar
Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost–utility analysis. Arch. Dis. Child. 88(10), 862–869 (2003).
PubMed Web of Science ®Google Scholar
Pradas-Velasco R, Antoñanzas-Villar F, Martínez-Zárate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics 26(1), 45–56 (2008).
PubMed Web of Science ®Google Scholar
Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115(8), 947–956 (2008).
PubMed Web of Science ®Google Scholar
Dasbach EJ, Largeron N, Elbasha EH. Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev. Pharmacoecon. Outcomes Res. 8(5), 491–500 (2008).
PubMedGoogle Scholar
Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH. The cost–effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac. J. Cancer Prev. 9(3), 459–466 (2008).
PubMedGoogle Scholar
Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH. The cost–effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J. Med. Econ. 13(1), 110–118 (2010).
PubMedGoogle Scholar
Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost–effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26(1), 128–139 (2007).
PubMed Web of Science ®Google Scholar
Olsen J, Jepsen MR. Human papillomavirus transmission and cost–effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int. J. Technol. Assess. Health Care 26(2), 183–191 (2010).
PubMed Web of Science ®Google Scholar
Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost–effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27(37), 5133–5141 (2009).
PubMed Web of Science ®Google Scholar
Valentim J, Sartori AM, de Soárez PC, Amaku M, Azevedo RS, Novaes HM. Cost–effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 26(49), 6281–6291 (2008).
PubMed Web of Science ®Google Scholar
Shim E, Galvani AP. Impact of transmission dynamics on the cost–effectiveness of rotavirus vaccination. Vaccine 27(30), 4025–4030 (2009).
PubMed Web of Science ®Google Scholar
Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost–effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis. 200(8), 1311–1317 (2009).
PubMed Web of Science ®Google Scholar
Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12(2), 226–233 (2009).
PubMed Web of Science ®Google Scholar
Perlroth DJ, Glass RJ, Davey VJ, Cannon D, Garber AM, Owens DK. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. Clin. Infect. Dis. 50(2), 165–174 (2010).
PubMed Web of Science ®Google Scholar
Brisson M, Edmunds WJ. The cost–effectiveness of varicella vaccination in Canada. Vaccine 20(7–8), 1113–1125 (2002).
PubMed Web of Science ®Google Scholar
Banz K, Wagenpfeil S, Neiss A et al. The cost–effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21(11–12), 1256–1267 (2003).
PubMed Web of Science ®Google Scholar
Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 8(3), 209–222 (2005).
PubMed Web of Science ®Google Scholar
de Vries R, Kretzschmar M, Schellekens JF et al. Cost–effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010).
PubMed Web of Science ®Google Scholar
Stevenson M, Beard S, Finn A, Brennan A. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine 20(13–14), 1778–1786 (2002).
PubMed Web of Science ®Google Scholar
Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost–effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J. Gastroenterol. 42(2), 152–160 (2007).
PubMed Web of Science ®Google Scholar
Thompson KM, Tebbens RJ. Retrospective cost–effectiveness analyses for polio vaccination in the United States. Risk Anal. 26(6), 1423–1440 (2006).
PubMed Web of Science ®Google Scholar
Beutels P, Gay NJ. Economic evaluation of options for measles vaccination strategy in a hypothetical western European country. Epidemiol. Infect. 130(2), 273–283 (2003).
PubMed Web of Science ®Google Scholar
Bishai D, Johns B, Nair D et al. The cost–effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J. Infect. Dis. 204(Suppl. 1), S107–S115 (2011).
PubMed Web of Science ®Google Scholar
Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13(1), 28–41 (2007).
PubMed Web of Science ®Google Scholar
Babigumira JB, Levin A, Burgess C et al. Assessing the cost–effectiveness of measles elimination in Uganda: local impact of a global eradication program. J. Infect. Dis. 204(Suppl. 1), S116–S123 (2011).
Google Scholar
Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, Nguyen VH. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS ONE 4(7), e6284 (2009).
PubMed Web of Science ®Google Scholar
De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost–effectiveness analysis. Vaccine 25(29), 5433–5440 (2007).
PubMed Web of Science ®Google Scholar
Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359(8), 821–832 (2008).
PubMed Web of Science ®Google Scholar
Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339, b3884 (2009).
PubMed Web of Science ®Google Scholar
Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10(11), 1915–1923 (2004).
PubMed Web of Science ®Google Scholar
Trotter CL, Edmunds WJ. Reassessing the cost–effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med. Decis. Making 26(1), 38–47 (2006).
PubMed Web of Science ®Google Scholar
Goldie SJ, Kim JJ, Kobus K et al. Cost–effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25(33), 6257–6270 (2007).
PubMed Web of Science ®Google Scholar
Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost–effectiveness analysis in a low-resource setting. Br. J. Cancer 97(9), 1322–1328 (2007).
PubMed Web of Science ®Google Scholar
Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost–effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18(23), 3263–3282 (1999).
PubMed Web of Science ®Google Scholar

Websites

National Health Service (NHS). NHS guide to the methods of technology appraisal. (2008). www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (Accessed 30 September 2010)
Google Scholar
National Institute for Health and Clinical Excellence (NICE). Single technology appraisal specification for manufacturer/sponsor submission of evidence. Draft (2008). www.nice.org.uk/media/E29/DF/SpecificationForManufacturerSponsorSubmissionofEvidenceDraft.pdf (Accessed 30 September 2010)
Google Scholar
Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH guidelines for the evaluation of health technologies: Canada (3rd Edition) (2006). www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf (Accessed 30 September 2010)
Google Scholar
Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version 4.3 (2008). www.health.gov.au/internet/main/publishing.nsf/content/pbacguidelines-index (Accessed 16 September 2011)
Google Scholar
Guidelines for pharmacoeconomic research, updated version (2006). www.ispor.org/PEguidelines/source/HTAGuidelinesNLupdated2006.pdf (Accessed 30 September 2010)
Google Scholar
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Health Care] (IQWiG). IQWiG methods for assessment of the relation of benefits to costs in the German statutory health care system. Version 1.0 (2008). www.iqwig.de/download/08-01-24_Draft_Methods_of_the_Relation_ of_Benefits_to_Costs_Version_1_0.pdf (Accessed 30 September 2010)
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date